PL3137097T3 - Leczenie i profilaktyka choroby Alzheimera (AD) - Google Patents
Leczenie i profilaktyka choroby Alzheimera (AD)Info
- Publication number
- PL3137097T3 PL3137097T3 PL15720058.5T PL15720058T PL3137097T3 PL 3137097 T3 PL3137097 T3 PL 3137097T3 PL 15720058 T PL15720058 T PL 15720058T PL 3137097 T3 PL3137097 T3 PL 3137097T3
- Authority
- PL
- Poland
- Prior art keywords
- alzheimer
- disease
- prevention
- treatment
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461985710P | 2014-04-29 | 2014-04-29 | |
| EP14166355 | 2014-04-29 | ||
| PCT/EP2015/059337 WO2015165964A1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of alzheimer's disease (ad) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3137097T3 true PL3137097T3 (pl) | 2023-09-11 |
Family
ID=50555097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15720058.5T PL3137097T3 (pl) | 2014-04-29 | 2015-04-29 | Leczenie i profilaktyka choroby Alzheimera (AD) |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10646565B2 (enExample) |
| EP (1) | EP3137097B1 (enExample) |
| JP (1) | JP2017514831A (enExample) |
| KR (1) | KR102460465B1 (enExample) |
| CN (1) | CN106535924A (enExample) |
| AU (3) | AU2015254661A1 (enExample) |
| CA (1) | CA2946929A1 (enExample) |
| ES (1) | ES2953381T3 (enExample) |
| PL (1) | PL3137097T3 (enExample) |
| WO (2) | WO2015165964A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106535924A (zh) | 2014-04-29 | 2017-03-22 | 阿费里斯股份公司 | 阿尔茨海默病(ad)的治疗和预防 |
| KR102506460B1 (ko) * | 2014-04-29 | 2023-03-03 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
| WO2015165966A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| EP3643319A1 (en) * | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994016327A1 (en) * | 1993-01-14 | 1994-07-21 | Pollard Harvey B | Methods and compositions for blocking amyloid protein ion channels |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6905686B1 (en) * | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| AT413946B (de) * | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
| US10383887B2 (en) * | 2008-02-20 | 2019-08-20 | New York University | Preventing and treating amyloid-beta deposition by stimulation of innate immunity |
| AT506820B1 (de) * | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
| AT506819B1 (de) * | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
| CN104436212A (zh) * | 2010-03-29 | 2015-03-25 | 诺华股份有限公司 | 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物 |
| EP2659908A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| KR102506460B1 (ko) * | 2014-04-29 | 2023-03-03 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
| WO2015165966A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| CN106535924A (zh) | 2014-04-29 | 2017-03-22 | 阿费里斯股份公司 | 阿尔茨海默病(ad)的治疗和预防 |
-
2015
- 2015-04-29 CN CN201580029876.1A patent/CN106535924A/zh active Pending
- 2015-04-29 WO PCT/EP2015/059337 patent/WO2015165964A1/en not_active Ceased
- 2015-04-29 CA CA2946929A patent/CA2946929A1/en not_active Abandoned
- 2015-04-29 AU AU2015254661A patent/AU2015254661A1/en not_active Abandoned
- 2015-04-29 EP EP15720058.5A patent/EP3137097B1/en active Active
- 2015-04-29 US US15/307,714 patent/US10646565B2/en active Active
- 2015-04-29 WO PCT/EP2015/059355 patent/WO2015165974A1/en not_active Ceased
- 2015-04-29 JP JP2016565238A patent/JP2017514831A/ja active Pending
- 2015-04-29 PL PL15720058.5T patent/PL3137097T3/pl unknown
- 2015-04-29 ES ES15720058T patent/ES2953381T3/es active Active
- 2015-04-29 KR KR1020167033323A patent/KR102460465B1/ko active Active
-
2020
- 2020-03-17 US US16/821,557 patent/US11147873B2/en active Active
-
2021
- 2021-01-08 AU AU2021200093A patent/AU2021200093B2/en active Active
- 2021-09-23 US US17/482,579 patent/US20220062412A1/en active Pending
-
2024
- 2024-02-20 AU AU2024201099A patent/AU2024201099A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN106535924A (zh) | 2017-03-22 |
| CA2946929A1 (en) | 2015-11-05 |
| KR102460465B1 (ko) | 2022-10-27 |
| AU2015254661A1 (en) | 2016-11-10 |
| JP2017514831A (ja) | 2017-06-08 |
| EP3137097A1 (en) | 2017-03-08 |
| AU2024201099A1 (en) | 2024-03-14 |
| WO2015165964A8 (en) | 2017-02-09 |
| WO2015165964A1 (en) | 2015-11-05 |
| EP3137097C0 (en) | 2023-06-21 |
| US10646565B2 (en) | 2020-05-12 |
| EP3137097B1 (en) | 2023-06-21 |
| AU2021200093B2 (en) | 2024-03-07 |
| US20220062412A1 (en) | 2022-03-03 |
| WO2015165974A1 (en) | 2015-11-05 |
| AU2015254661A9 (en) | 2019-08-01 |
| US11147873B2 (en) | 2021-10-19 |
| ES2953381T3 (es) | 2023-11-13 |
| US20200338192A1 (en) | 2020-10-29 |
| AU2021200093A1 (en) | 2021-03-18 |
| KR20160145820A (ko) | 2016-12-20 |
| US20170056495A1 (en) | 2017-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL247085B (en) | Methods for treating Alzheimer's disease | |
| IL276315A (en) | Donepezil preparations and a method for treating Alzheimer's disease | |
| ZA201605341B (en) | Methods of treating alzheimer's disease | |
| IL266047A (en) | Methods and preparations for the treatment of Fabry disease | |
| EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
| IL248592A0 (en) | Treatment of Crohn's disease using delayed-release 6-mercaptofurin | |
| EP3137097C0 (en) | TREATMENT AND PREVENTION OF ALZHEIMER | |
| IL248935A0 (en) | Diagnostic testing and treatment/prevention of Alzheimer's disease | |
| PT3458045T (pt) | Ebselen para uso no tratamento da doença de ménière | |
| PL3137094T3 (pl) | Leczenie i profilaktyka choroby alzheimera (ad) | |
| IL254252A0 (en) | History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease | |
| PL3352742T3 (pl) | Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona | |
| SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
| PT3137093T (pt) | Tratamento e prevenção da doença de alzheimer (da) | |
| IL251135A (en) | A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| GB201511453D0 (en) | Treatment of alzheimer's disease | |
| GB201621398D0 (en) | Treatment of emt-associated disease | |
| GB201504144D0 (en) | Treatment of Parkinson's disease | |
| AU2015904411A0 (en) | Compositions and methods for the treatment of Alzheimer's disease | |
| GB201518052D0 (en) | Parkinson's disease treatment | |
| GB201610906D0 (en) | Treatment of cardiovascular disease | |
| GB201504413D0 (en) | Treatment of disease | |
| HK1230506A1 (en) | Treatment of crohn's disease with delayed-release 6-mercaptopurine |